Literature DB >> 9822630

Characterization of isoleucyl-tRNA synthetase from Staphylococcus aureus. II. Mechanism of inhibition by reaction intermediate and pseudomonic acid analogues studied using transient and steady-state kinetics.

A J Pope1, K J Moore, M McVey, L Mensah, N Benson, N Osbourne, N Broom, M J Brown, P O'Hanlon.   

Abstract

The interactions of isoleucyl-tRNA synthetase (IleRS, E) from Staphylococcus aureus with both intermediate analogues and pseudomonic acid (PS-A) have been investigated using transient and steady-state techniques. Non-hydrolyzable analogues of isoleucyl-AMP (I) were simple competitive inhibitors (Ile-ol-AMP, Ki = 50 nM and Ile-NHSO2-AMP, Ki = 1 nM;). PS-A (J) inhibits IleRS via a slow-tight binding competitive mechanism where E.J (Kj = approximately 2 nM), undergoes an isomerization to form a stabilized E*.J complex (K*j = 50 pM). To overcome tight-binding artifacts when K*j << [E], K*j values were estimated from PPi/ATP exchange where [S] >> Km, thus raising K*j,app well above [E]. Using [3H]PS-A, it was confirmed that binding occurs with 1:1 stoichiometry and is reversible. Formation of inhibitor complexes was monitored directly through changes in enzyme tryptophan fluorescence. For Ile-ol-AMP and Ile-NHSO2-AMP, the fluorescence intensity of E.I was identical to that when E.Ile-AMP forms catalytically. Binding of PS-A induced only a small change in IleRS fluorescence that was characterized using transient kinetic competition. SB-205952, a PS-A analogue, produced a 37% quenching of IleRS fluorescence upon binding as a result of radiationless energy transfer. Inhibitor reversal rates were obtained by measuring relaxation between spectroscopically different complexes. Together, these data represent a comprehensive solution to the kinetics of inhibition by these compounds.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9822630     DOI: 10.1074/jbc.273.48.31691

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  16 in total

1.  Amplification of the gene for isoleucyl-tRNA synthetase facilitates adaptation to the fitness cost of mupirocin resistance in Salmonella enterica.

Authors:  Wilhelm Paulander; Dan I Andersson; Sophie Maisnier-Patin
Journal:  Genetics       Date:  2010-02-22       Impact factor: 4.562

Review 2.  Asparagine synthetase chemotherapy.

Authors:  Nigel G J Richards; Michael S Kilberg
Journal:  Annu Rev Biochem       Date:  2006       Impact factor: 23.643

3.  Antitubercular nucleosides that inhibit siderophore biosynthesis: SAR of the glycosyl domain.

Authors:  Ravindranadh V Somu; Daniel J Wilson; Eric M Bennett; Helena I Boshoff; Laura Celia; Brian J Beck; Clifton E Barry; Courtney C Aldrich
Journal:  J Med Chem       Date:  2006-12-28       Impact factor: 7.446

4.  Inhibition of methionyl-tRNA synthetase by REP8839 and effects of resistance mutations on enzyme activity.

Authors:  Louis S Green; James M Bullard; Wendy Ribble; Frank Dean; David F Ayers; Urs A Ochsner; Nebojsa Janjic; Thale C Jarvis
Journal:  Antimicrob Agents Chemother       Date:  2008-11-17       Impact factor: 5.191

5.  Transcriptional regulation and signature patterns revealed by microarray analyses of Streptococcus pneumoniae R6 challenged with sublethal concentrations of translation inhibitors.

Authors:  Wai-Leung Ng; Krystyna M Kazmierczak; Gregory T Robertson; Raymond Gilmour; Malcolm E Winkler
Journal:  J Bacteriol       Date:  2003-01       Impact factor: 3.490

6.  Optimization of Methionyl tRNA-Synthetase Inhibitors for Treatment of Cryptosporidium Infection.

Authors:  Frederick S Buckner; Ranae M Ranade; J Robert Gillespie; Sayaka Shibata; Matthew A Hulverson; Zhongsheng Zhang; Wenlin Huang; Ryan Choi; Christophe L M J Verlinde; Wim G J Hol; Atsuko Ochida; Yuichiro Akao; Robert K M Choy; Wesley C Van Voorhis; Sam L M Arnold; Rajiv S Jumani; Christopher D Huston; Erkang Fan
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

Review 7.  Progress and challenges in aminoacyl-tRNA synthetase-based therapeutics.

Authors:  Christopher S Francklyn; Patrick Mullen
Journal:  J Biol Chem       Date:  2019-01-22       Impact factor: 5.157

Review 8.  Recent development of leucyl-tRNA synthetase inhibitors as antimicrobial agents.

Authors:  Panpan Zhang; Shutao Ma
Journal:  Medchemcomm       Date:  2019-05-27       Impact factor: 3.597

9.  Mode of action and biochemical characterization of REP8839, a novel inhibitor of methionyl-tRNA synthetase.

Authors:  Urs A Ochsner; Casey L Young; Kimberley C Stone; Frank B Dean; Nebojsa Janjic; Ian A Critchley
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

10.  N-Leucinyl Benzenesulfonamides as Structurally Simplified Leucyl-tRNA Synthetase Inhibitors.

Authors:  Michael H Charlton; Rihards Aleksis; Adélaïde Saint-Leger; Arya Gupta; Einars Loza; Lluís Ribas de Pouplana; Ilze Kaula; Daina Gustina; Marina Madre; Daina Lola; Kristaps Jaudzems; Grace Edmund; Christopher P Randall; Louise Kime; Alex J O'Neill; Wil Goessens; Aigars Jirgensons; Paul W Finn
Journal:  ACS Med Chem Lett       Date:  2018-01-18       Impact factor: 4.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.